DCOY
NASDAQDecoy Therapeutics Inc.
Price$2.80-5.30 (-65.43%)
2026-06-052026-09-09
News · 26 weeks44+11%
2026-03-152026-09-06
Mix2790d
- Insider11(41%)
- SEC Filings10(37%)
- Other6(22%)
Latest news
25 items- INSIDERDirector Lieber Jonathan I was granted 2,000 shares, increasing direct ownership by 100,000% to 2,002 units (SEC Form 4)4 - Decoy Therapeutics Inc. (0001615219) (Issuer)
- INSIDERChief Business Officer Marschel Peter Klaus was granted 3,900 shares (SEC Form 4)4 - Decoy Therapeutics Inc. (0001615219) (Issuer)
- INSIDERChief Executive Officer Pierce Frederick Ii was granted 33,455 shares, increasing direct ownership by 2,409% to 34,844 units (SEC Form 4)4 - Decoy Therapeutics Inc. (0001615219) (Issuer)
- INSIDERChief Financial Officer Rosenblum Mark J was granted 9,682 shares, increasing direct ownership by 576% to 11,363 units (SEC Form 4)4 - Decoy Therapeutics Inc. (0001615219) (Issuer)
- INSIDERChief Scientific Officer Hibner Barbara Louise was granted 4,216 shares (SEC Form 4)4 - Decoy Therapeutics Inc. (0001615219) (Issuer)
- INSIDERDirector Hanish Arnold C was granted 3,000 shares, increasing direct ownership by 718% to 3,418 units (SEC Form 4)4 - Decoy Therapeutics Inc. (0001615219) (Issuer)
- INSIDERDirector Lammers Paul was granted 2,000 shares, increasing direct ownership by 200,000% to 2,001 units (SEC Form 4)4 - Decoy Therapeutics Inc. (0001615219) (Issuer)
- INSIDERDirector Burleson Tess was granted 2,000 shares, increasing direct ownership by 100,000% to 2,002 units (SEC Form 4)4 - Decoy Therapeutics Inc. (0001615219) (Issuer)
- INSIDERDirector Mcvicar William K. was granted 3,000 shares, increasing direct ownership by 150,000% to 3,002 units (SEC Form 4)4 - Decoy Therapeutics Inc. (0001615219) (Issuer)
- INSIDERDirector Gauthier Patricia G. was granted 2,000 shares (SEC Form 4)4 - Decoy Therapeutics Inc. (0001615219) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Decoy Therapeutics Inc.SCHEDULE 13G - Decoy Therapeutics Inc. (0001615219) (Subject)
- SECSEC Form 10-Q filed by Decoy Therapeutics Inc.10-Q - Decoy Therapeutics Inc. (0001615219) (Filer)
- SECSEC Form DEF 14A filed by Decoy Therapeutics Inc.DEF 14A - Decoy Therapeutics Inc. (0001615219) (Filer)
- SECSEC Form DEFA14A filed by Decoy Therapeutics Inc.DEFA14A - Decoy Therapeutics Inc. (0001615219) (Filer)
- PRDecoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ PlatformPortfolio now spans seven patent families and 19 pending applications across seven jurisdictions, protecting antiviral peptide conjugates, the methods used to make them, their formulations, and the design platform behind themCAMBRIDGE, Mass., Aug. 3, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ:DCOY), a biotechnology company developing Designable Multi-Antivirals (D-MAVs™), today announced continued expansion of its intellectual property portfolio, which now comprises seven patent families covering compositions of matter, methods of manufacture, formulations, and the company's IMP³ACT™ design platform. The portfolio inc
- INSIDERSEC Form 3 filed by new insider Gauthier Patricia G.3 - Decoy Therapeutics Inc. (0001615219) (Issuer)
- PRDecoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health ThreatsLead D-MAV demonstrates cross-viral family fusion inhibition, validating theplatform; opens a new program in filovirus pandemic preparednessCAMBRIDGE, Mass., July 27, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ:DCOY), a biotechnology company developing Designable Multi-Antivirals (D-MAVs™), today announced that one of its D-MAV candidates demonstrates in vitro activity against wild-type Ebola Zaire virus in testing at the Texas Biomedical Research Institute. Building on the result, Decoy has opened an exploratory program to design D-MAVs against filoviruses, including Ebola and Marburg. The candidate was engineered on
- SECSEC Form PRE 14A filed by Decoy Therapeutics Inc.PRE 14A - Decoy Therapeutics Inc. (0001615219) (Filer)
- SECSEC Form EFFECT filed by Decoy Therapeutics Inc.EFFECT - Decoy Therapeutics Inc. (0001615219) (Filer)
- SECSEC Form 424B3 filed by Decoy Therapeutics Inc.424B3 - Decoy Therapeutics Inc. (0001615219) (Filer)
- SECSEC Form 8-K filed by Decoy Therapeutics Inc.8-K - Decoy Therapeutics Inc. (0001615219) (Filer)
- PRDecoy Therapeutics Stockholders Elect Patricia Gauthier to Board of DirectorsCAMBRIDGE, Mass., July 15, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ:DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms, today announced that stockholders elected Patricia Gauthier, MBA, LL.B., as a Class II director at the Company's 2026 Annual Meeting of Stockholders, held July 14, 2026 Ms. Gauther will serve with the Company's other two Class II directors, Rick Pierce and Jon Lieber, each of whom were re-elected at the annual meeting. "Patricia has spent her career making sure important medicines reach the peopl
- SECSEC Form S-1 filed by Decoy Therapeutics Inc.S-1 - Decoy Therapeutics Inc. (0001615219) (Filer)
- PR4 Sizzling Biotech and Healthcare Companies Reporting Strategic MilestonesDENVER, June 29, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives are highlighting continued activity across the biotechnology and healthcare sectors, as companies work to expand pipelines, strengthen balance sheets, and advance toward commercialization. Universe Pharmaceuticals (NASDAQ:UPC) announced a definitive agreement to acquire Best Praise International Limited, a transaction that would add five China-based pharmaceutical patents to the company's intellectual property portfolio. The all-stock acquisition, valued at approximately $10.7
- SECDecoy Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Decoy Therapeutics Inc. (0001615219) (Filer)
DCOY FAQ
6 questionsWhere does DCOY stock trade?
Decoy Therapeutics Inc. (DCOY) is listed on NASDAQ.What sector and industry is DCOY in?
Decoy Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Decoy Therapeutics Inc. go public?
Decoy Therapeutics Inc. (DCOY) completed its IPO in 2015.What are analysts saying about DCOY?
Decoy Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from Ladenburg Thalmann: Buy with a $250.00 price target on 2026-01-23. Recent price targets cluster around $250.00.What companies are similar to DCOY?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare DCOY side-by-side with any of them on Quantisnow.How can I track DCOY on Quantisnow?
Quantisnow aggregates Decoy Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DCOY to receive live email and push alerts on every new disclosure.